Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis
- PMID: 36483232
- PMCID: PMC9724718
- DOI: 10.4081/dr.2022.9469
Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis
Abstract
More than a skin disease, psoriasis is also considered a systemic disorder. Lipocalin-2, an adipokine, may be a link between psoriasis and systemic inflammation. We conducted this study to measure the plasma level of lipocalin-2 and investigate its relationship with the clinical manifestations in patients with psoriasis. We assessed 62 patients with psoriasis and 31 healthy controls. Their demographic information and clinical characteristics were determined by physical examination and review of the recorded medical history. Plasma lipocalin-2 levels were measured using an enzyme-linked immunosorbent assay. Plasma lipocalin-2 concentration was significantly higher in patients with psoriasis than in the control group (P<0.001). Patients with acute psoriatic subgroups, including psoriatic erythroderma and pustular psoriasis, had significantly higher plasma lipocalin-2 levels than those with the chronic plaque type. In addition, plasma lipocalin-2 concentration positively correlates with the disease severity index, including the psoriasis area severity index, body surface area, high-sensitivity C-reactive protein, nail psoriasis severity index, and pustular severity index. In patients with psoriasis, increased plasma lipocalin-2 levels correlated with severity and indicated an active disease state. These findings suggest that lipocalin-2 may play an important role in determining the pathogenesis of acute psoriasis and may serve as a valuable clinical biomarker of this disease.
Keywords: Adipokines; Comorbiditity; Inflammation; Lipocalin-2; Psoriasis.
©Copyright: the Author(s).
Figures

Similar articles
-
Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels.J Dermatolog Treat. 2017 Mar;28(2):136-140. doi: 10.1080/09546634.2016.1180340. Epub 2016 May 11. J Dermatolog Treat. 2017. PMID: 27165470
-
Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome.Arch Dermatol Res. 2014 Apr;306(3):239-45. doi: 10.1007/s00403-013-1414-x. Epub 2013 Sep 20. Arch Dermatol Res. 2014. PMID: 24052155
-
Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI.Arch Dermatol Res. 2013 Mar;305(2):105-12. doi: 10.1007/s00403-012-1306-5. Epub 2012 Dec 16. Arch Dermatol Res. 2013. PMID: 23242471
-
Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis.J Inflamm Res. 2022 Mar 31;15:2157-2166. doi: 10.2147/JIR.S358492. eCollection 2022. J Inflamm Res. 2022. PMID: 35386225 Free PMC article. Review.
-
Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis.J Dermatolog Treat. 2022 Jun;33(4):1967-1974. doi: 10.1080/09546634.2021.1966357. Epub 2021 Dec 22. J Dermatolog Treat. 2022. PMID: 34369253 Review.
Cited by
-
Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis.Life (Basel). 2023 Sep 6;13(9):1873. doi: 10.3390/life13091873. Life (Basel). 2023. PMID: 37763277 Free PMC article.
-
Clinical application of serum biomarkers for detecting and monitoring of chronic plaque psoriasis.Front Mol Biosci. 2023 Jul 21;10:1196323. doi: 10.3389/fmolb.2023.1196323. eCollection 2023. Front Mol Biosci. 2023. PMID: 37546687 Free PMC article. Review.
-
Psoriasis: What Is New in Markers of Disease Severity?Medicina (Kaunas). 2024 Feb 18;60(2):337. doi: 10.3390/medicina60020337. Medicina (Kaunas). 2024. PMID: 38399624 Free PMC article. Review.
References
-
- Sewon Kang, Masayuki Amagai, Anna L., Bruckner, et al. . Psoriasis. Fitzpatrick’s Dermatology. 1. 9th ed. United States: Mc Graw Hill Education; 2019. p. 457-97.
-
- Lynde CW, Poulin Y, Vender R, et al. . Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014;71:141-50. - PubMed
-
- Gisondi P, Fostini AC, Fossa I, et al. . Psoriasis and the metabolic syndrome. Clin Dermatol 2018;36:21-8. - PubMed
-
- Coimbra S., Catarino C., Santos-Silva A. The triad psoriasis-obesityadipokine profile. J Eur Acad Dermatol Venereol 2016;30:1876-85. - PubMed
-
- Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Experim Dermatol 2011;20:303-7. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials